Skip to main content
Premium Trial:

Request an Annual Quote

ProtoNet, Protein Data Bank, Amersham Biosciences


A new version of the protein sequence classification system ProtoNet is now available at This new version, ProtoNet v3.0, can automatically classify over 1 million proteins from UniProt. The classifications are made based on hierarch-ical clustering. The new version also allows users to add their own new proteins and fit them in with existing entries. New users are advised to go to the guided tour and site map at and

The Protein Data Bank’s January 2004 release of data is now available on CD-ROM. Four products make up the release: Release 107F includes the full set of experiment-ally determined structures and models that were deposited in the PDB by Jan. 1, 2004 in a six-disk set. Release 107F-EXP contains the full set of deposited data, plus X-ray structure factors and NMR constraints in a nine-disk set. Release 107U contains the incremental set of structures and models deposited between Oct. 1, 2003 and Jan. 1, 2004 on a single disk. Release 107U-EXP contains the experimental data, X-ray structure factors, and NMR constraints deposited between Oct. 1, 2003 and Jan. 1, 2004. Information on ordering can be found at

Amersham Biosciences has released Glutathione Sepharose High Performance, a new medium for improved resolution in the purification of GST-tagged proteins. The medium consists of highly cross-linked 34 µm agarose beads with a glutathione immobilized to each. GST-tagged recombinant proteins bind to the bead, allowing them to be purified from cellular contaminants. The small bead size also provides for separated peaks, the company said. Glutathione Sepharose High Performance will be available in packs of 25 ml and 100 ml, or as pre-packed 1 ml or 5 ml columns.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.